Related Experiment Video

Updated: Aug 7, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with

Toru Sugiyama

    International Journal of Clinical Oncology
    |July 20, 2006
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
    09:40

    Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

    Published on: August 2, 2024

    Related Experiment Videos

    Last Updated: Aug 7, 2026

    Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
    07:54

    Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

    Published on: October 25, 2011

    Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
    09:40

    Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

    Published on: August 2, 2024

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Efficient PNA double-duplex invasion using preQ1•G-clamp as a pseudo-complementary G•C base pair.

    Bioorganic & medicinal chemistry letters·2026

    Prognostic impact of lymphadenectomy in patients with advanced ovarian clear cell carcinoma: an ancillary analysis of the JGOG3017-A4 study.

    International journal of clinical oncology·2025

    Y-box binding protein 1/cyclin A1 axis specifically promotes cell cycle progression at G2/M phase in ovarian cancer.

    Scientific reports·2024

    Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study.

    Journal of gynecologic oncology·2024

    Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: practical biomarkers and robust multiplex models.

    International journal of clinical oncology·2024

    A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study).

    Cancers·2023

    Multigene panel testing for hereditary tumor syndromes: an engine for stratified, preemptive cancer medicine in Japan.

    International journal of clinical oncology·2026

    Re-evaluating the neutropenia-survival paradigm in irinotecan-based therapy for advanced gastric cancer: post-hoc analysis of the RINDBeRG trial.

    International journal of clinical oncology·2026

    Electronic patient-reported outcome monitoring and quality of life during later-line nivolumab therapy for advanced gastric cancer.

    International journal of clinical oncology·2026

    Safety and efficacy of neoadjuvant S-1 and oxaliplatin therapy for gastric cancer in the elderly: combined phase II trials of KSCC1601 and KSCC1801.

    International journal of clinical oncology·2026

    A prospective study evaluating the impact of waiting time on blood testing and clinical workflows in cancer patients.

    International journal of clinical oncology·2026

    Efficacy and safety of lisocabtagene maraleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: 31-month follow-up of the phase 2 TRANSCEND FL study.

    International journal of clinical oncology·2026

    Interaction between severe postoperative complications and adjuvant chemotherapy on overall survival after upfront resection of pancreatic ductal adenocarcinoma.

    Frontiers in medicine·2026

    mRNA-dendritic cell antigen vaccine potentiates CD38 CAR-T Cell therapy for relapsed/refractory acute myeloid leukemia.

    Theranostics·2026

    Liver-resident cellular determinants of oncolytic virotherapy in hepatocellular carcinoma: viral susceptibility and spatial immune remodeling.

    Frontiers in cell and developmental biology·2026

    Chemokines as regulators of CAR-T cell trafficking, function, and context-dependent tumor cell death.

    Frontiers in immunology·2026

    Distinct prognostic impact of circumferential resection margin and adverse histologic features after intersphincteric resection for ultra-low rectal cancer following chemoradiotherapy: a retrospective cohort study.

    Annals of surgical treatment and research·2026

    Efficacy of the Peritoneovenous Shunt as Palliative Care for Patients with Advanced Cancer with Refractory Ascites: A Randomized Controlled Trial (JIVROSG-0803 Study).

    Interventional radiology (Higashimatsuyama-shi (Japan)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us